GILD has gotten a couple good headlines recently.
@T2Kplus20 thoughts?
GILD is a great company that recently dipped due to its transition in focus - diversifying away from HCV and one big clinical fail several months ago. Regardless, it still has a robust and promising pipeline. Today's data announcement is big. The preliminary data was so positive, they stopped the trial to give the new product to all participants (which is inline with ethical and moral guidelines).
The company is likely undervalued.
Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV Prevention
PURPOSE 1 met its key efficacy endpoints of superiority of twice-yearly lenacapavir to once-daily oral Truvada® (emtricitabine 200mg and tenofovir disoproxil fumarate 300mg; F/TDF) and background HIV incidence (bHIV). Based on these results, the independent Data Monitoring Committee (DMC) recommended that Gilead stop the blinded phase of the trial and offer open-label lenacapavir to all participants.
“With zero infections and 100% efficacy, twice-yearly lenacapavir has demonstrated its potential as an important new tool to help prevent HIV infections,” said Merdad Parsey, MD, PhD, Chief Medical Officer, Gilead Sciences. “We look forward to additional results from the ongoing PURPOSE clinical program and continuing toward our goal of helping to end the HIV epidemic for everyone, everywhere.”